Dienny Rodrigues de Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dienny Rodrigues de Souza has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Alves de Oliveira
Institute of Tropical Pathology and Public Health, Federal University of Goiás, CEP: 74605-050, Goiânia, Goiás, Brazil
1 shared publication - Célia Maria de Almeida Soares
Tropical Medicine Post-Graduate Program, Federal University of Goiás, Goiânia, Goiás, 74690-900, Brazil
1 shared publication - Katheryne Lohany Barros Barbosa
Laboratory of Molecular Biology, Institute of Biological Sciences, Federal University of Goiás, Goiás 74690-900, Brazil
1 shared publication - Kleber Santiago Freitas Silva
Univ Fed Goias, Inst Ciencias Biol, Goiania, GO, Brazil
1 shared publication - Lívia Do Carmo Silva
Center for the Study and Research of (Re)Emerging Agents, Federal University of Goiás, Goiânia, Brazil
1 shared publication - Marcos Antonio Batista de Carvalho Júnior
Laboratório de Biologia Molecular, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia 74690-900, GO, Brazil
1 shared publication
Latest Publications
- Open Access
- 19 November 2020
- Published by MDPI AG in Journal of Fungi
- Vol. 6 (4) , 300
Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability in target tissues, have become evident in clinical settings. These factors, added to the fact that Paracoccidioidomycosis (PCM) therapy is a long process, lasting from months to years, emphasize the need for the research and development of new molecules. Researchers have concentrated efforts on the identification of new compounds using numerous tools and targeting important proteins from Paracoccidioides, with the emphasis on enzymatic pathways absent in humans. This review aims to discuss the aspects related to the identification of compounds, methodologies, and perspectives when proposing new antifungal agents against PCM.
- 19 November 2020
- Published by MDPI AG in Journal of Fungi
- Vol. 6 (4) , 300
Open AccessOverview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability in target tissues, have become evident in clinical settings. These factors, added to the fact that Paracoccidioidomycosis (PCM) therapy is a long process, lasting from months to years, emphasize the need for the research and development of new molecules. Researchers have concentrated efforts on the identification of new compounds using numerous tools and targeting important proteins from Paracoccidioides, with the emphasis on enzymatic pathways absent in humans. This review aims to discuss the aspects related to the identification of compounds, methodologies, and perspectives when proposing new antifungal agents against PCM.